Craig J. Hartley Ph.D Rejoins Endovasc's Scientific Advisory Committee.

MONTGOMERY, Texas -- Endovasc Inc. (OTCBB: EVSC), an early-stage drug development company that pioneers new cardiovascular and metabolic drug therapies, is pleased to announce that Craig J. Hartley Ph.D. has rejoined the Company's Scientific Advisory Committee. Dr. Hartley is currently a Professor of Cardiovascular Sciences in the Department of Medicine of Baylor College of Medicine in Houston, TX. He has also been a member of the National Institutes of Health's Study Section for Small Business Innovation Research proposals for over a decade.

Since 1970 Dr. Hartley has been involved in the design, development, application, and commercialization of ultrasonic instrumentation for cardiovascular measurements. A major interest has been the miniaturization of ultrasonic sensors for catheter and implantable devices used in both clinical and research applications. Several of these sensors and systems are now being manufactured and are used in several thousand laboratories worldwide.

Dr. Hartley has four patents granted for devices and probes in the area of transluminal angioplasty as well as one for an implantable biological sensor probe, and an epicardial and multifunctional probe. Additionally, Dr. Hartley's work has been cited in over 150 publications in medical journals, reports, and books throughout his career. His most recent publications and professional accomplishments show a concentration on works relating to cardiovascular functions, cardiac electrophysiology, and the design of several Doppler ultrasound techniques, sensors and velocimeters.

President and Chief Executive Officer of Endovasc, Dr. Diane Dottavio commented, "We are very pleased that Dr. Hartley has chosen to continue to serve as a member of the advisory committee. Dr. Hartley is a true pioneer in this field as he was the first to bring many types of Doppler instrumentation and ultrasonic systems into practice both in laboratories and in the operating room. His vast experience in the design, construction and commercialization of instrumentation for cardiovascular measurements will be extremely valuable to Endovasc's efforts."

About Endovasc, Inc.

Endovasc, Inc., established in 1996, is a Business Development Company focused on innovative drug development in the areas of cardiovascular and metabolic medicine. Endovasc's Subsidiaries include: Angiogenix Limited which retains the sublicense for an isomer of nicotine that has shown to recruit the body's own stem cells that help grow new blood vessels, aiming to relieve chest pain and improve heart function in patients with chronic myocardial ischemia; Liprostin Incorporated, which holds the intellectual property for a liposomal based treatment to increase circulation, and reduce leg pain in patients suffering from vascular disease; and Nutraceutical Development Corporation which has an agreement in place with an innovative product development company to commercialize its muscle mass enhancing product. Endovasc recently announced its intention to create a new subsidiary to showcase its promising ProStent technology with is a patented stent coating comprised of a polymer and prostaglandin E1 (PGE1).

For more information about Endovasc, please visit www.endovasc.com.

Safe Harbor Statement

All statements other than statements of historical fact included in this press release are ``forward-looking statements.'' The forward-looking statements, including statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements (i.e., future operational results and sales) are subject to assumptions and beliefs based on current information known to the Company and factors that are subject to uncertainties, risk and other influences, which are outside the Company's control, and may yield results differing materially from those anticipated.